{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:12:32Z","timestamp":1773839552061,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000180","name":"U.S. Department of Homeland Security Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010219","name":"Bavarian Nordic","doi-asserted-by":"publisher","award":["HSHQDC-12-C-00051"],"award-info":[{"award-number":["HSHQDC-12-C-00051"]}],"id":[{"id":"10.13039\/501100010219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010219","name":"Bavarian Nordic","doi-asserted-by":"publisher","award":["HSHQDC-14-F-00035"],"award-info":[{"award-number":["HSHQDC-14-F-00035"]}],"id":[{"id":"10.13039\/501100010219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.vaccine.2019.10.103","type":"journal-article","created":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T08:07:59Z","timestamp":1573286879000},"page":"769-778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of modified Vaccinia Ankara-based vaccines against foot-and-mouth disease serotype A24 in cattle"],"prefix":"10.1016","volume":"38","author":[{"given":"Robin","family":"Steigerwald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Brake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Barrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Schutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Kalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia T.","family":"Wennier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariane","family":"Volkmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Hurtle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariceny","family":"Zurita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melia","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5667-8027","authenticated-orcid":false,"given":"Barbara J.","family":"Kamicker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9634-9001","authenticated-orcid":false,"given":"Michael C.","family":"Puckette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max V.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0360-5040","authenticated-orcid":false,"given":"John G.","family":"Neilan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.10.103_b0005","unstructured":"OIE. World Organisation for Animal Health. Foot and Mouth Disease 2013 [accessed 01 July 2019]. Available from: http:\/\/www.oie.int\/fileadmin\/Home\/eng\/Animal_Health_in_the_World\/docs\/pdf\/Disease_cards\/FOOT_AND_MOUTH_DISEASE.pdf."},{"issue":"44","key":"10.1016\/j.vaccine.2019.10.103_b0010","first-page":"187","article-title":"Research on foot-and-mouth disease. III. The cultivation of the virus on a practical scale in explantations of bovine tongue epithelium","volume":"12","author":"Frenkel","year":"1951","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2019.10.103_b0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coviro.2018.02.005","article-title":"The need for improved vaccines against foot-and-mouth disease","volume":"29","author":"de Los","year":"2018","journal-title":"Curr Opin Virol"},{"issue":"48","key":"10.1016\/j.vaccine.2019.10.103_b0020","doi-asserted-by":"crossref","first-page":"7345","DOI":"10.1016\/j.vaccine.2018.10.031","article-title":"Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine","volume":"36","author":"Barrera","year":"2018","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2019.10.103_b0025","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.vaccine.2018.01.026","article-title":"Use of ENABL(R) adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine","volume":"36","author":"Barrera","year":"2018","journal-title":"Vaccine"},{"issue":"27","key":"10.1016\/j.vaccine.2019.10.103_b0030","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1016\/j.vaccine.2015.12.018","article-title":"Multiple efficacy studies of an adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle using homologous challenge","volume":"34","author":"Schutta","year":"2016","journal-title":"Vaccine"},{"issue":"Pt 12","key":"10.1016\/j.vaccine.2019.10.103_b0035","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1099\/0022-1317-76-12-3089","article-title":"Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system","volume":"76","author":"Abrams","year":"1995","journal-title":"J Gen Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.10.103_b0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1006\/viro.1999.9717","article-title":"Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs","volume":"259","author":"Sanz-Parra","year":"1999","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2019.10.103_b0045","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.virol.2004.01.027","article-title":"Immunogenicity and T cell recognition in swine of foot-and-mouth disease virus polymerase 3D","volume":"322","author":"Garcia-Briones","year":"2004","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2019.10.103_b0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.antiviral.2013.02.016","article-title":"Capripoxvirus-vectored vaccines against livestock diseases in Africa","volume":"98","author":"Boshra","year":"2013","journal-title":"Antiviral Res"},{"issue":"39","key":"10.1016\/j.vaccine.2019.10.103_b0055","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1016\/j.vaccine.2013.03.020","article-title":"Clinical development of modified Vaccinia virus Ankara vaccines","volume":"31","author":"Gilbert","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.103_b0060","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified Vaccinia Virus Ankara: history, value in basic research, and current perspectives for vaccine development","volume":"97","author":"Volz","year":"2017","journal-title":"Adv Virus Res"},{"issue":"1","key":"10.1016\/j.vaccine.2019.10.103_b0065","first-page":"24","article-title":"Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures","volume":"195","author":"Mayr","year":"1964","journal-title":"Zentralbl Bakteriol Orig"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2019.10.103_b0070","first-page":"375","article-title":"The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralbl Bakteriol B"},{"issue":"2","key":"10.1016\/j.vaccine.2019.10.103_b0075","doi-asserted-by":"crossref","first-page":"e0192312","DOI":"10.1371\/journal.pone.0192312","article-title":"A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates","volume":"13","author":"Callendret","year":"2018","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.vaccine.2019.10.103_b0080","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/infdis\/jiy214","article-title":"Induction of cross-clade antibody and T-cell responses by a modified Vaccinia virus Ankara-based influenza A(H5N1) vaccine in a randomized phase 1\/2a clinical trial","volume":"218","author":"de Vries","year":"2018","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2019.10.103_b0085","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13567-018-0516-z","article-title":"Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination","volume":"49","author":"Lorenzo","year":"2018","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2019.10.103_b0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.vetimm.2017.01.004","article-title":"Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine","volume":"185","author":"Lopera-Madrid","year":"2017","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2019.10.103_b0095","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2018.04.015","article-title":"The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host","volume":"154","author":"Calvo-Pinilla","year":"2018","journal-title":"Antiviral Res"},{"issue":"15","key":"10.1016\/j.vaccine.2019.10.103_b0100","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified Vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"issue":"34","key":"10.1016\/j.vaccine.2019.10.103_b0105","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1016\/j.vaccine.2018.06.064","article-title":"Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses","volume":"36","author":"Hu","year":"2018","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2019.10.103_b0110","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jinf.2019.02.003","article-title":"Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults","volume":"78","author":"Green","year":"2019","journal-title":"J Infect"},{"issue":"12","key":"10.1016\/j.vaccine.2019.10.103_b0115","doi-asserted-by":"crossref","first-page":"e0208328","DOI":"10.1371\/journal.pone.0208328","article-title":"First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5\u201317 months old infants and children","volume":"13","author":"Tiono","year":"2018","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.vaccine.2019.10.103_b0120","doi-asserted-by":"crossref","first-page":"e0181578","DOI":"10.1371\/journal.pone.0181578","article-title":"Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-cell vaccines employing prime-boost regimens","volume":"12","author":"Tan","year":"2017","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.vaccine.2019.10.103_b0125","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1128\/jvi.64.2.748-756.1990","article-title":"Foot-and-mouth disease virus protease 3C induces specific proteolytic cleavage of host cell histone H3","volume":"64","author":"Falk","year":"1990","journal-title":"J Virol"},{"issue":"21","key":"10.1016\/j.vaccine.2019.10.103_b0130","doi-asserted-by":"crossref","first-page":"11721","DOI":"10.1128\/JVI.01355-13","article-title":"Foot-and-mouth disease virus 3C protease induces fragmentation of the Golgi compartment and blocks intra-Golgi transport","volume":"87","author":"Zhou","year":"2013","journal-title":"J Virol"},{"issue":"19","key":"10.1016\/j.vaccine.2019.10.103_b0135","doi-asserted-by":"crossref","first-page":"9907","DOI":"10.1128\/JVI.00756-10","article-title":"Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice","volume":"84","author":"Meisinger-Henschel","year":"2010","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2019.10.103_b0140","doi-asserted-by":"crossref","first-page":"e73511","DOI":"10.1371\/journal.pone.0073511","article-title":"A novel naturally occurring tandem promoter in modified Vaccinia virus Ankara drives very early gene expression and potent immune responses","volume":"8","author":"Wennier","year":"2013","journal-title":"PLoS ONE"},{"issue":"Pt 12","key":"10.1016\/j.vaccine.2019.10.103_b0145","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1099\/vir.0.83156-0","article-title":"Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara","volume":"88","author":"Meisinger-Henschel","year":"2007","journal-title":"J Gen Virol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2019.10.103_b0150","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.vetimm.2006.10.002","article-title":"Production and characterization of two serotype independent monoclonal antibodies against foot-and-mouth disease virus","volume":"115","author":"Yang","year":"2007","journal-title":"Vet Immunol Immunopathol"},{"issue":"6","key":"10.1016\/j.vaccine.2019.10.103_b0155","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1128\/jvi.64.6.3108-3111.1990","article-title":"Transient dominant selection of recombinant vaccinia viruses","volume":"64","author":"Falkner","year":"1990","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2019.10.103_b0160","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jviromet.2012.11.011","article-title":"Efficient production of foot-and-mouth disease virus empty capsids in insect cells following down regulation of 3C protease activity","volume":"187","author":"Porta","year":"2013","journal-title":"J Virol Methods"},{"issue":"22","key":"10.1016\/j.vaccine.2019.10.103_b0165","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00924-17","article-title":"Foot-and-mouth disease (FMD) virus 3C protease mutant L127P: implications for FMD vaccine development","volume":"91","author":"Puckette","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.10.103_b0170","unstructured":"OIE. Foot and mouth disease (infection with foot and mouth disease virus). Chapter 3.1.8. Paris, France: World Organisation for Animal Health; 2018. [accessed 01 July 2019]. Available from: http:\/\/www.oie.int\/fileadmin\/Home\/eng\/Health_standards\/tahm\/3.01.08_FMD.pdf."},{"issue":"Pt 2","key":"10.1016\/j.vaccine.2019.10.103_b0175","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1099\/0022-1317-79-2-347","article-title":"Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells","volume":"79","author":"Drexler","year":"1998","journal-title":"J Gen Virol"},{"issue":"11","key":"10.1016\/j.vaccine.2019.10.103_b0180","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2460\/javma.2002.220.1636","article-title":"Use of a portable real-time reverse transcriptase-polymerase chain reaction assay for rapid detection of foot-and-mouth disease virus","volume":"220","author":"Callahan","year":"2002","journal-title":"J Am Vet Med Assn"},{"issue":"6209","key":"10.1016\/j.vaccine.2019.10.103_b0185","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/337709a0","article-title":"The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution","volume":"337","author":"Acharya","year":"1989","journal-title":"Nature"},{"issue":"47\u201348","key":"10.1016\/j.vaccine.2019.10.103_b0190","doi-asserted-by":"crossref","first-page":"6966","DOI":"10.1016\/j.vaccine.2006.04.050","article-title":"Comparative evaluation of six ELISAs for the detection of antibodies to the non-structural proteins of foot-and-mouth disease virus","volume":"24","author":"Brocchi","year":"2006","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2019.10.103_b0195","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1099\/0022-1317-47-2-485","article-title":"Cellular differences in the molecular mechanisms of vaccinia virus host range restriction","volume":"47","author":"Hruby","year":"1980","journal-title":"J Gen Virol"},{"issue":"52","key":"10.1016\/j.vaccine.2019.10.103_b0200","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1016\/j.vaccine.2009.05.095","article-title":"Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain","volume":"27","author":"Suter","year":"2009","journal-title":"Vaccine"},{"issue":"6 Pt 2","key":"10.1016\/j.vaccine.2019.10.103_b0205","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1083\/jcb.127.6.1829","article-title":"Maturation of the trans-Golgi network protease furin: compartmentalization of propeptide removal, substrate cleavage, and COOH-terminal truncation","volume":"127","author":"Vey","year":"1994","journal-title":"J Cell Biol"},{"key":"10.1016\/j.vaccine.2019.10.103_b0210","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/B978-0-12-386497-0.00004-9","article-title":"Control of gene expression by translational recoding","volume":"86","author":"Dinman","year":"2012","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.10.103_b0215","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/JVI.01587-06","article-title":"Structural and mutagenic analysis of foot-and-mouth disease virus 3C protease reveals the role of the beta-ribbon in proteolysis","volume":"81","author":"Sweeney","year":"2007","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2019.10.103_b0220","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1128\/jvi.71.12.9743-9752.1997","article-title":"Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: the structure of empty capsids of foot-and-mouth disease virus","volume":"71","author":"Curry","year":"1997","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2019.10.103_b0225","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12026-018-8991-x","article-title":"Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice","volume":"66","author":"Magnusson","year":"2018","journal-title":"Immunol Res"},{"issue":"16","key":"10.1016\/j.vaccine.2019.10.103_b0230","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.vaccine.2009.02.006","article-title":"Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs","volume":"27","author":"Kyriakis","year":"2009","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2019.10.103_b0235","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1002\/eji.201040453","article-title":"Concomitant type I IFN receptor-triggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankara-induced T-cell expansion","volume":"40","author":"Frenz","year":"2010","journal-title":"Eur J Immunol"},{"issue":"25","key":"10.1016\/j.vaccine.2019.10.103_b0240","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1016\/j.vaccine.2007.04.002","article-title":"Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge","volume":"25","author":"Antonis","year":"2007","journal-title":"Vaccine"},{"issue":"34","key":"10.1016\/j.vaccine.2019.10.103_b0245","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1016\/j.vaccine.2018.07.047","article-title":"N-terminal domain of Schmallenberg virus envelope protein Gc delivered by recombinant equine herpesvirus type 1 and modified vaccinia virus Ankara: immunogenicity and protective efficacy in cattle","volume":"36","author":"Wernike","year":"2018","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19315051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19315051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:37:24Z","timestamp":1759401444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19315051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0264410X19315051"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.103","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of modified Vaccinia Ankara-based vaccines against foot-and-mouth disease serotype A24 in cattle","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}